Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the business’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $8.63, for a total transaction of $2,248,978.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Bros. Advisors Lp Baker also recently made the following trade(s):
- On Friday, January 19th, Bros. Advisors Lp Baker sold 880,735 shares of Bellicum Pharmaceuticals stock. The stock was sold at an average price of $8.20, for a total transaction of $7,222,027.00.
Bellicum Pharmaceuticals Inc (BLCM) traded down $0.13 during mid-day trading on Monday, reaching $5.62. 508,839 shares of the company traded hands, compared to its average volume of 1,060,000. The firm has a market capitalization of $186.73, a price-to-earnings ratio of -1.88 and a beta of 0.70. The company has a current ratio of 6.08, a quick ratio of 6.08 and a debt-to-equity ratio of 0.23. Bellicum Pharmaceuticals Inc has a 1-year low of $5.02 and a 1-year high of $15.55.
BLCM has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. SunTrust Banks cut their price target on shares of Bellicum Pharmaceuticals to $18.00 and set a “buy” rating on the stock in a report on Wednesday, January 31st. Raymond James Financial reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, December 12th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, BidaskClub lowered shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Bellicum Pharmaceuticals has a consensus rating of “Hold” and an average target price of $15.43.
Hedge funds have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. lifted its holdings in Bellicum Pharmaceuticals by 47.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock valued at $1,516,000 after buying an additional 41,995 shares during the period. Virtu KCG Holdings LLC acquired a new position in Bellicum Pharmaceuticals in the second quarter valued at $728,000. HighTower Advisors LLC acquired a new position in Bellicum Pharmaceuticals in the second quarter valued at $448,000. Vanguard Group Inc. lifted its holdings in Bellicum Pharmaceuticals by 13.6% in the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock valued at $14,092,000 after buying an additional 144,854 shares during the period. Finally, Northern Trust Corp lifted its holdings in Bellicum Pharmaceuticals by 29.5% in the second quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock valued at $3,989,000 after buying an additional 77,760 shares during the period. Institutional investors and hedge funds own 55.21% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/12/bros-advisors-lp-baker-sells-260600-shares-of-bellicum-pharmaceuticals-inc-blcm-stock.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.